Phase II trial of oral etoposide in recurrent or refractory endometrial adenocarcinoma: A Southwest Oncology Group study

Elizabeth A. Poplin, P. Y. Liu, James E. Delmore, Sharon Wilczynski, Dennis F. Moore, Ronald K. Potkul, Bruce A. Fine, Edward V. Hannigan, David S. Alberts

Research output: Contribution to journalArticle

18 Scopus citations

Abstract

Oral etoposide has activity in a wide variety of tumors and is well tolerated. Therefore, the efficacy of oral etoposide was assessed as a treatment of metastatic endometrial cancer. To be eligible for this group- wide Southwest Oncology Group trial, patients had to have histologically proven metastatic or recurrent endometrial carcinoma; no previous cytotoxic therapy; and adequate renal, hepatic, and hematologic function, and they had to have given informed consent. Therapy consisted of oral etoposide, 50 mg daily on days 1-21 on a 28-day schedule. Therapy was continued in the absence of toxicity or disease progression. Forty-four eligible women, with a median age of 68 years (range 38-84 years) were treated. Radiotherapy had been delivered to 33 and hormonal therapy to 21. The median duration of therapy was 69 days (range 7-510 days). The treatment was well tolerated. Only one patient had grade 4 neutropenia, and a second had grade 4 anemia. Three patients had grade 3 nausea. One complete and five partial responses (14%) were observed. An additional four patients had unconfirmed responses. Tumor regressions were noted in nodes, bone, and visceral organs. While oral etoposide has only a modest level of activity when used in chemonaive patients, the minimal toxicity of this drug makes it a candidate for use in combination chemotherapy.

Original languageEnglish (US)
Pages (from-to)432-435
Number of pages4
JournalGynecologic Oncology
Volume74
Issue number3
DOIs
StatePublished - Sep 1999

All Science Journal Classification (ASJC) codes

  • Obstetrics and Gynecology
  • Oncology

Fingerprint Dive into the research topics of 'Phase II trial of oral etoposide in recurrent or refractory endometrial adenocarcinoma: A Southwest Oncology Group study'. Together they form a unique fingerprint.

  • Cite this

    Poplin, E. A., Liu, P. Y., Delmore, J. E., Wilczynski, S., Moore, D. F., Potkul, R. K., Fine, B. A., Hannigan, E. V., & Alberts, D. S. (1999). Phase II trial of oral etoposide in recurrent or refractory endometrial adenocarcinoma: A Southwest Oncology Group study. Gynecologic Oncology, 74(3), 432-435. https://doi.org/10.1006/gyno.1999.5461